Erika Rich | Authors

HER2+ MBC: Preparing Patients for Chemotherapy

March 10, 2022

Adverse events commonly associated with chemotherapies used to treat HER2-positive metastatic breast cancer, and recommendations to help equip patients with knowledge about what to expect during their treatment journey.

Subcutaneous Therapies for HER2+ MBC

March 03, 2022

Julia A. LaBarbera, NP, reacts to the treatment approach used for a patient with HER2-positive metastatic breast cancer, and highlights the benefits of new subcutaneous injections of trastuzumab and pertuzumab that are available.